Bioverativ Therapeutics Overview

  • Status
  • Acquired/​Merged

  • Employees
  • 500

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 3

  • Investments
  • 2

Bioverativ Therapeutics General Information

Description

Provider of biotechnology services intended to address various issues related to the treatment of chronic blood disorders. The company's biotechnology services include offering therapies, clinical trials, research and development of treatment methods for the treatment of cold agglutinin disease, sickle cell disease and beta-thalassemia, enabling medical institutions and patients to get a wide range of scientific treatments to fight fatal blood diseases.

Contact Information

Formerly Known As
Biogen
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 225 Second Avenue
  • Waltham, MA 02451
  • United States
+1 (781)
Primary Industry
Biotechnology
Acquirer
Sanofi
Vertical(s)
Corporate Office
  • 225 Second Avenue
  • Waltham, MA 02451
  • United States
+1 (781)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bioverativ Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Bioverativ Therapeutics‘s full profile, request access.

Request a free trial

Bioverativ Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Provider of biotechnology services intended to address various issues related to the treatment of chronic blood disorder
Biotechnology
Waltham, MA
500 As of 2018

King Of Prussia, PA
 

Barga, Italy
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bioverativ Therapeutics Competitors (21)

One of Bioverativ Therapeutics’s 21 competitors is CSL Behring, a Corporation company based in King Of Prussia, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CSL Behring Corporation King Of Prussia, PA
Kedrion Private Equity-Backed Barga, Italy
CSL Behring (Biotechnology) Corporation Vienna, Austria
UCB Corporation Brussels, Belgium
Pfizer (Vienna) Corporation Vienna, Austria
You’re viewing 5 of 21 competitors. Get the full list »

Bioverativ Therapeutics Patents

Bioverativ Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024405184-A1 Antibodies and assays for determining clotting factor viii activity Pending 18-Dec-2023
EP-4828724-A1 Antibodies and assays for determining clotting factor viii activity Pending 18-Dec-2023
WO-2025137044-A1 Antibodies and assays for determining clotting factor viii activity Inactive 18-Dec-2023
EP-4659256-A2 Methods for treating hemophilia a and estimating bleed risk and uses thereof Pending 01-Feb-2023
US-20260066131-A1 Methods for treating hemophilia a and estimating bleed risk and uses thereof Pending 01-Feb-2023 G16H50/30
To view Bioverativ Therapeutics’s complete patent history, request access »

Bioverativ Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bioverativ Therapeutics Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Bioverativ Therapeutics‘s full profile, request access.

Request a free trial

Bioverativ Therapeutics Investments & Acquisitions (2)

Bioverativ Therapeutics’s most recent deal was a Corporate Asset Purchase with Amunix (Royalties). The deal was made on 01-Jan-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Amunix (Royalties) 01-Jan-2018 Corporate Asset Purchase Buildings and Property
True North Therapeutics 28-Jun-2017 Merger/Acquisition Drug Discovery
To view Bioverativ Therapeutics’s complete investments and acquisitions history, request access »

Bioverativ Therapeutics FAQs

  • Where is Bioverativ Therapeutics headquartered?

    Bioverativ Therapeutics is headquartered in Waltham, MA.

  • What is the size of Bioverativ Therapeutics?

    Bioverativ Therapeutics has 500 total employees.

  • What industry is Bioverativ Therapeutics in?

    Bioverativ Therapeutics’s primary industry is Biotechnology.

  • Is Bioverativ Therapeutics a private or public company?

    Bioverativ Therapeutics is a Private company.

  • What is the current valuation of Bioverativ Therapeutics?

    The current valuation of Bioverativ Therapeutics is .

  • What is Bioverativ Therapeutics’s current revenue?

    The current revenue for Bioverativ Therapeutics is .

  • Who are Bioverativ Therapeutics’s investors?

    Biogen, Fidelity Equity Partners (Massachusetts), Jennison Associates, and ValueAct Capital Management have invested in Bioverativ Therapeutics.

  • Who are Bioverativ Therapeutics’s competitors?

    CSL Behring, Kedrion, CSL Behring (Biotechnology), UCB, and Pfizer (Vienna) are some of the 21 competitors of Bioverativ Therapeutics.

  • When was Bioverativ Therapeutics acquired?

    Bioverativ Therapeutics was acquired on 08-Mar-2018.

  • Who acquired Bioverativ Therapeutics?

    Bioverativ Therapeutics was acquired by Sanofi.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process